| scholarly article | Q13442814 |
| P50 | author | Kimiko Murofushi | Q17218104 |
| P2093 | author name string | Yuko Fujiwara | |
| Junming Yue | |||
| Duane D Miller | |||
| Mari Gotoh | |||
| Renuka Gupte | |||
| Ayako Uchiyama | |||
| Gabor J Tigyi | |||
| James Fells | |||
| Jianxiong Liu | |||
| Jonathan Wall | |||
| Louisa Balazs | |||
| Renukadevi Patil | |||
| Stephen Kennel | |||
| SueChin Lee | |||
| P2860 | cites work | Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein | Q24299154 |
| Structural basis of substrate discrimination and integrin binding by autotaxin | Q24337236 | ||
| Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production | Q24673806 | ||
| Crystal structure of autotaxin and insight into GPCR activation by lipid mediators | Q27666524 | ||
| The emerging role of lysophosphatidic acid in cancer | Q28191543 | ||
| Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase | Q28217851 | ||
| Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate | Q28239967 | ||
| Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression | Q28299091 | ||
| Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts | Q30436718 | ||
| Role of LPA4/p2y9/GPR23 in negative regulation of cell motility | Q30440331 | ||
| Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation | Q33548625 | ||
| Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model | Q33759458 | ||
| Phospholipase Cgamma activation drives increased production of autotaxin in endothelial cells and lysophosphatidic acid-dependent regression. | Q33826570 | ||
| Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases | Q34148745 | ||
| Aiming drug discovery at lysophosphatidic acid targets | Q34339759 | ||
| Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid | Q34580111 | ||
| The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases | Q34687134 | ||
| The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation | Q34776268 | ||
| Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo | Q36246828 | ||
| Inhibition of transcellular tumor cell migration and metastasis by novel carba-derivatives of cyclic phosphatidic acid | Q36246888 | ||
| Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis | Q36421116 | ||
| Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity | Q36452780 | ||
| Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells | Q36742070 | ||
| Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect | Q37194251 | ||
| Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs | Q37439765 | ||
| Specific increase in serum autotaxin activity in patients with pancreatic cancer | Q39570170 | ||
| Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells. | Q39652665 | ||
| Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells | Q39748143 | ||
| Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. | Q39905542 | ||
| Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers | Q40391221 | ||
| LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). | Q40416729 | ||
| Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. | Q40731719 | ||
| Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development | Q41490870 | ||
| Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain | Q41955077 | ||
| Low-density lipoprotein-cholesterol/high-density lipoprotein-cholesterol ratio predicts lipid-rich coronary plaque in patients with coronary artery disease--integrated-backscatter intravascular ultrasound study | Q43059380 | ||
| Expression of sphingosine-1-phosphate receptors and lysophosphatidic acid receptors on cultured and xenografted human colon, breast, melanoma, and lung tumor cells | Q43060718 | ||
| Plasma lysophosphatidic acid concentration and ovarian cancer | Q44031447 | ||
| Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression | Q44747935 | ||
| Lysophospholipids are potential biomarkers of ovarian cancer | Q44973063 | ||
| Expression of autotaxin, an ectoenzyme that produces lysophosphatidic acid, in human placenta. | Q45926672 | ||
| Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. | Q45989475 | ||
| Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. | Q46424226 | ||
| Autotaxin as a novel serum marker of liver fibrosis. | Q51490124 | ||
| Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. | Q52012908 | ||
| Correlations between c-myc gene copy-number and clinicopathological parameters of ovarian tumours | Q58050609 | ||
| Both Plasma Lysophosphatidic Acid and Serum Autotaxin Levels are Increased in Chronic Hepatitis C | Q59939737 | ||
| Hepatoma cell migration through a mesothelial cell monolayer is inhibited by cyclic AMP-elevating agents via a Rho-dependent pathway | Q73163403 | ||
| Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells | Q73253526 | ||
| Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers | Q77204834 | ||
| Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids | Q80476879 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 31-36 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Biochemical Society Transactions | Q864226 |
| P1476 | title | Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis | |
| P478 | volume | 40 |
| Q35908698 | Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers |
| Q90387906 | Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma |
| Q42909461 | Allergic to autotaxin. A new role for lysophospholipase d and lysophosphatidic Acid in asthma? |
| Q92445149 | Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface |
| Q34980426 | Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis |
| Q39266426 | Autotaxin inhibitors: a patent review (2012-2016). |
| Q58105355 | Autotaxin is a novel molecular identifier of type I endometrial cancer |
| Q38223013 | Design of anticancer lysophosphatidic acid agonists and antagonists |
| Q38389922 | G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease |
| Q36110170 | HACD1, a regulator of membrane composition and fluidity, promotes myoblast fusion and skeletal muscle growth. |
| Q37422766 | Hits of a High-Throughput Screen Identify the Hydrophobic Pocket of Autotaxin/Lysophospholipase D As an Inhibitory Surface |
| Q64955683 | LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling. |
| Q98178012 | Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry |
| Q39237720 | Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index |
| Q38101074 | Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays. |
| Q28545165 | Lysophosphatidic acid alters the expression profiles of angiogenic factors, cytokines, and chemokines in mouse liver sinusoidal endothelial cells |
| Q33689905 | Lysophosphatidic acid enhanced the angiogenic capability of human chondrocytes by regulating Gi/NF-kB-dependent angiogenic factor expression |
| Q38834081 | Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells |
| Q37486804 | Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression |
| Q27313853 | Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal |
| Q38660494 | Molecular mechanisms of target recognition by lipid GPCRs: relevance for cancer |
| Q38817086 | PI3K is required for both basal and LPA-induced DNA synthesis in oral carcinoma cells |
| Q38320338 | Promising pharmacological directions in the world of lysophosphatidic Acid signaling |
| Q34516098 | Protection of Neuroblastoma Neuro2A Cells from Hypoxia-Induced Apoptosis by Cyclic Phosphatidic Acid (cPA) |
| Q26741062 | Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivo |
| Q91654129 | Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis |
| Q33786333 | Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells |
| Q64227597 | Serum ATX as a novel biomarker for breast cancer |
| Q35708420 | Small lipidated anti-obesity compounds derived from neuromedin U. |
| Q37527792 | The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation |
| Q37711207 | The gep proto-oncogene Gα12 mediates LPA-stimulated activation of CREB in ovarian cancer cells |
| Q38246634 | The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer |
| Q38151635 | Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5'-nucleotidase, and alkaline phosphatase inhibitors |
| Q35756057 | c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas |
Search more.